Skip to main content

Table 2 Characteristics of the study subjects.

From: In vitroprediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study

Patients Group A
n = 9
Group B
n = 4
Group C
n = 5
p
Group A vs. B
p
Group A vs. C
p
Group B vs. C
Age 15.4(4.2) 12(1.8) 16.5(1.7) NS NS NS
CFCS 31(8) 26(2) 24(2) NS NS NS
FEV1 (%) 69(21) 80(12) 74(10) NS NS NS
FVC (%) 70(20) 83(7) 84(22) NS NS NS
FEF25–75 (%) 46(30) 67(26) 54(26) NS NS NS
  1. Group A: patients with the Y122X stop mutation. Group B: patients with another stop mutation. Group C: patients without any stop mutation. CFCS refers to the Cystic Fibrosis Clinical Score. FEV1, FVC, FEF25–75 refer respectively to forced expiratory volume in one second, forced vital capacity, and forced expiratory flow at 25 to 75 percent of vital capacity and are expressed as percentages of predicted values for age, sex, and height. NS: non-significant. Data are described as mean (SD)